4 results
The primary objective is to investigate the safety and efficacy of LDE225 with respect to overall response rate according to independent central review (ICR).The key secondary objective is to assess LDE225 with respect to progression-free survival (…
To establish the MTD and/or recommended phase II dose of the coadministration of LDE225 and INC424 in patients with MF, who have not previously received therapy with a JAK inhibitor
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
The aim of this study is to assess for the first time in humans, the safety and feasibility of the EndoRotor® for the ablation of Barrett*s esophagus.